ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, enhances the activity of multiple standard of care modalities

被引：0
|
作者：
Lewis, Katherine [1 ]
Maurer, Mark [1 ]
Mudri, Sherri [1 ]
Susmilch, Kayla [1 ]
Ahmed-Qadri, Fariha [1 ]
Gudgeon, Chelsea [1 ]
Levin, Steven [1 ]
Wolfson, Martin [1 ]
Dillon, Stacey [1 ]
Swiderek, Kristine [1 ]
Peng, Stanford [1 ]
机构：
[1] Alpine Immune Sci, Seattle, WA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P467
引用
收藏
页数：2
相关论文
共 21 条
  • [1] First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies.
    Moser, Justin C.
    Voskoboynik, Mark
    Lakhani, Nehal J.
    Millward, Michael
    Davar, Diwakar
    Harb, Wael A.
    Yang, Jing
    Means, Gary
    Manjarrez, Kristi
    Tercero, Almudena
    Zayed, Hany
    Hillson, Jan
    Dela Cruz, Christine
    Perez, Graciela Noemi
    Peng, Stanford L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)
    Millward, Michael
    Moser, Justin C.
    Davar, Diwakar
    Voskoboynik, Mark
    Lakhani, Nehal J.
    Sanborn, Rachel E.
    Grewal, Jaspreet
    Narayan, Ajita
    Sznol, Mario
    Schieber, Keren
    Zayed, Hany
    Dela Cruz, Christine
    Perez, Graciela
    Peng, Stanford L.
    CANCER RESEARCH, 2022, 82 (12)
  • [3] ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, utilizes multiple mechanisms to elicit potent anti-tumor immunity superior to checkpoint blockade alone
    Maurer, Mark
    Gudgeon, Chelsea
    Lewis, Katherine
    Mudri, Sherri
    Dillon, Stacey
    Wolfson, Martin
    Levin, Steven
    Swiderek, Kristine
    Peng, Stanford
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] A STUDY OF ALPN-202, A PD-L1-DEPENDENT CD28 COSTIMULATOR AND DUAL CHECKPOINT INHIBITOR, IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANCIES
    Lakhani, Nehal
    McKean, Meredith
    Patnaik, Amita
    Manjarrez, Kristi
    Zayed, Hany
    Chisamore, Michael
    Peng, Stanford
    Goldberg, Zelanna
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A529 - A529
  • [5] NEON-1: a first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies.
    Voskoboynik, Mark
    Moser, Justin C.
    Lakhani, Nehal
    Millward, Michael
    Davar, Diwakar
    Harb, Wael A.
    Yang, Jing
    Means, Gary
    Manjarrez, Kristi
    Tercero, Almudena
    Zayed, Hany
    Hillson, Jan
    Dela Cruz, Christine
    Perez, Graciela
    Peng, Stanford L.
    CANCER RESEARCH, 2021, 81 (13)
  • [6] Davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies (NEON-2)
    Patnaik, Amita
    Lakhani, Nehal J.
    McKean, Meredith
    Gainor, Justin F.
    Buu, Cathy Vo
    Dillon, Stacey R.
    Zayed, Hany
    Chisamore, Michael Jon
    Pluda, James Michael
    Peng, Stanford L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)
    Davar, Diwakar
    Moser, Justin C.
    Millward, Michael
    Voskoboynik, Mark
    Lakhani, Nehal J.
    Sanborn, Rachel E.
    Grewal, Jaspreet Singh
    Narayan, Ajita
    Sznol, Mario
    Dillon, Stacey R.
    Schieber, Keren
    Zayed, Hany
    Dela Cruz, Christine Marie
    Perez, Graciela Noemi
    Peng, Stanford L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
    Cavalcante, Ludimila
    Chandana, Sreenivasa
    Lakhani, Nehal
    Enstrom, Amanda
    LeBlanc, Heidi
    Schmalz, Joseph
    Lengyel, Krisztina
    Schneider, Frank
    Thomas, Heather
    Chisamore, Michael J.
    Peng, Stanford L.
    Naumovski, Allison
    Davar, Diwakar
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08) : 1 - 6
  • [9] INTERIM DOSE ESCALATION OF DAVOCETICEPT, A CONDITIONAL CD28 COSTIMULATOR AND DUAL CHECKPOINT INHIBITOR, IN COMBINATION WITH PEMBROLIZUMAB IN ADVANCED MALIGNANCIES (NEON-2)
    Lakhani, Nehal
    Patnaik, Amita
    McKean, Meredith
    Gainor, Justin
    Buu, Cathy Vo
    Enstrom, Amanda
    Davies, Rupert
    Dillon, Stacey
    Zayed, Hany
    Chisamore, Michael
    Pluda, James Michael
    Naumovski, Allison
    Peng, Stanford
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A771 - A771
  • [10] PRECLINICAL PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION OF ALPN-202, A DUAL PD-L1/CTLA-4 ANTAGONIST AND PD-L1-DEPENDENT CD28 T CELL COSTIMULATOR, TO SUPPORT FIRST-IN-HUMAN CLINICAL TRIAL DESIGN.
    Yang, J.
    Zhao, B.
    Lewis, K.
    Maurer, M.
    Seaberg, M.
    Susmilch, K.
    Swanson, R.
    Wolfson, M.
    Dillon, S.
    Peng, S. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S115 - S115
123